Innate Pharma S.A. (IPHA)
Market Cap | 166.75M |
Revenue (ttm) | 68.49M |
Net Income (ttm) | -8.41M |
Shares Out | 80.95M |
EPS (ttm) | -0.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 155 |
Open | 2.060 |
Previous Close | 2.080 |
Day's Range | 2.060 - 2.080 |
52-Week Range | 1.810 - 3.290 |
Beta | 0.71 |
Analysts | Strong Buy |
Price Target | 11.50 (+458.25%) |
Earnings Date | Mar 21, 2024 |
About IPHA
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an... [Read more]
Financial Performance
In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for IPHA stock is "Strong Buy" and the 12-month stock price forecast is $11.5.
News
![](https://cdn.snapi.dev/images/v1/p/t/press15-2481272.jpg)
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that updated efficacy and safety results ...
![](https://cdn.snapi.dev/images/v1/b/8/press1-2460550.jpg)
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced favorable results from the Phase 2 TELLOMAK stu...
![](https://cdn.snapi.dev/images/v1/4/8/conf13-2449174.jpg)
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.
![](https://cdn.snapi.dev/images/v1/c/z/press20-2446770.jpg)
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate's drug ca...
![](https://cdn.snapi.dev/images/v1/j/b/press10-2446328.jpg)
Outcome of Innate Pharma's 2024 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2024 Annual General Meeting.
![](https://cdn.snapi.dev/images/v1/z/n/press20-2440751.jpg)
Innate Pharma: Clarification Regarding SAR443579 Designation
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that in an abstract published on 14 May 2...
![](https://cdn.snapi.dev/images/v1/2/e/press6-2431297.jpg)
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drug ca...
![](https://cdn.snapi.dev/images/v1/r/l/press6-2428609.jpg)
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the...
![](https://cdn.snapi.dev/images/v1/r/d/conf16-2413790.jpg)
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for Q1 business update.
![](https://cdn.snapi.dev/images/v1/w/n/press13-2370726.jpg)
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024.
![](https://cdn.snapi.dev/images/v1/w/1/press14-2370727.jpg)
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the P...
![](https://cdn.snapi.dev/images/v1/8/s/press1-2364474.jpg)
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that first preclinical data for i...
![](https://cdn.snapi.dev/images/v1/z/y/conf13-2362289.jpg)
Innate Pharma Announces Its Participation in Upcoming Investor Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming Investor Conference.
![](https://cdn.snapi.dev/images/v1/t/8/press15-2357984.jpg)
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F.
![](https://cdn.snapi.dev/images/v1/v/3/press18-2334521.jpg)
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma reports Full Year 2023 financial results and business update.
![](https://cdn.snapi.dev/images/v1/m/u/conf9-2330162.jpg)
Innate Pharma Announces Its Participation to Upcoming Investor Conference
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are sc...
![](https://cdn.snapi.dev/images/v1/g/m/conf17-2323573.jpg)
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference ...
![](https://cdn.snapi.dev/images/v1/h/z/press4-2310118.jpg)
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma
MARSEILLE, France--(BUSINESS WIRE)--First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma.
![](https://cdn.snapi.dev/images/v1/q/o/conf6-2310116.jpg)
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024.
![](https://cdn.snapi.dev/images/v1/q/o/press17-2215791.jpg)
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Admin...
![](https://cdn.snapi.dev/images/v1/z/8/press15-2215789.jpg)
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company's le...
![](https://cdn.snapi.dev/images/v1/y/0/press2-2201271.jpg)
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to lice...
![](https://cdn.snapi.dev/images/v1/5/g/press4-2199440.jpg)
Innate Pharma Announces Leadership Change
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Mondher Mahjoubi has resigned from his position as Chief Execu...
![](https://cdn.snapi.dev/images/v1/r/a/press1-2190526.jpg)
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the updated efficacy and safety results from an open-...
![](https://cdn.snapi.dev/images/v1/a/u/press4-2190254.jpg)
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK s...